Jessica J. Federer

Aspivix is a medical device company in women’s health, based in Switzerland and in California, developing next-generation devices for gynecology. Our flagship product, carevix®, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more. Recognized as one the Best Inventions 2024 by TIME, carevix® is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. carevix® study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions. More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a womans anatomy or pain, and yet it is still considered to be the standard of care in gynecology. At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.

Pluto Health is on a mission to connect people to the right care they need--at the right time. Whether it’s preventive health or access to lifesaving treatments, we strive to deliver meaningful support for patients by leveraging best practices in clinical informatics and clinical care. Please be aware that there are fraudulent entities who are falsely claiming to be or represent Pluto Health recruiting in order to solicit sensitive personal information or payment. Pluto Health is not in any way associated with these entities or practices. Pluto Health will NEVER ask for personal information, including but not limited to financial information, via email or Microsoft Teams. If you suspect you are a victim of this scamming, we encourage you to cease further contact and report the crime to The Federal Trade Commission.

Aspivix is a medical device company in women’s health, based in Switzerland and in California, developing next-generation devices for gynecology. Our flagship product, carevix®, is the world’s first suction cervical stabilizer clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynecology, including IUD insertion, hysteroscopy, cervical biopsies, fertility treatments, and more. Recognized as one the Best Inventions 2024 by TIME, carevix® is a medical device that has received in 2023 FDA-clearance for the US market, as well as the CE-Mark for the European countries. carevix® study published in the international journal, Contraception, in March 2023 demonstrated superiority over the use of a single tooth tenaculum, reducing the pain by up to 73% and the bleeding by up to 83% in IUD insertions. More than 120 million women worldwide have procedures using the antiquated single-tooth tenaculum, an instrument invented over a century ago, without consideration of a womans anatomy or pain, and yet it is still considered to be the standard of care in gynecology. At Aspivix, we think women deserve more. We are driven by our vision to make gynecology modern.

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and change how brain disorders are thought about and treated. Our mission is to pioneer solutions with the potential to deliver life-changing brain health medicines, so every person can thrive. Welcome To The Workplace With A Difference At Sage, we believe that life is more than just a destination. We’re concerned with the journey, and we care deeply about everyone contributing to and benefiting from our own company journey. This means helping people discover the right path for them and carefully guiding colleagues along the way. Read our Community Guidelines: http://bit.ly/2tFyAoj

Pluto Health is on a mission to connect people to the right care they need--at the right time. Whether it’s preventive health or access to lifesaving treatments, we strive to deliver meaningful support for patients by leveraging best practices in clinical informatics and clinical care. Please be aware that there are fraudulent entities who are falsely claiming to be or represent Pluto Health recruiting in order to solicit sensitive personal information or payment. Pluto Health is not in any way associated with these entities or practices. Pluto Health will NEVER ask for personal information, including but not limited to financial information, via email or Microsoft Teams. If you suspect you are a victim of this scamming, we encourage you to cease further contact and report the crime to The Federal Trade Commission.

Angelini Ventures is the venture capital arm of Angelini Industries funded with a €300 million capital commitment to build and invest in early-stage companies that develop innovative ideas and solutions in biotechnology, digital health and life sciences. Angelini Ventures invests across Europe, North America, and Israel with a focus on brain health and consumer segments such as women, children and the elderly. The company is headquartered in Rome with a global team spread across Europe, Asia and the US to provide global perspective and capabilities.

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma’s technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.